Kazuto Harada1, Xuemei Wang2, Yusuke Shimodaira1, Tara Sagebiel3, Manoop S Bhutani4, Jeffrey H Lee4, Brian Weston4, Elena Elimova1, Quan Lin1, Fatemeh G Amlashi1, Dilsa Mizrak Kaya1, Anthony Lopez1, Mariela A Blum Murphy1, Jack A Roth5, Stephen G Swisher5, Heath D Skinner6, Wayne L Hofstetter5, Jane E Rogers7, Irene Thomas1, Dipen M Maru8, Ritsuko Komaki6, Garrett Walsh5, Jaffer A Ajani9. 1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Gastroenterology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. jajani@mdanderson.org.
Abstract
BACKGROUND: Early metabolic response after preoperative induction chemotherapy (IC) appears to predict histologic response and prognosis in esophageal cancer (EC), but the usefulness of this approach needs further development. OBJECTIVE: We evaluated metabolic response after one cycle of IC using positron emission tomography (PET) to correlate PET response and outcomes. PATIENTS AND METHODS: We retrospectively analyzed PET data from a randomized phase 2 trial (NCT00525915) of chemoradiation and surgery with or without IC for the treatment of EC. PET was performed at baseline, after one cycle of IC, and 5-7 weeks after chemoradiation. The relationship between PET response (≥35% reduction in standardized uptake value [SUV]) after IC and treatment response was analyzed. RESULTS: In 63 patients who received IC, the mean initial SUVmax prior to treatment was 11.9 ± 8.04 and mean SUVmax after one cycle of IC was 6.47 ± 4.45. The mean SUV reduction after IC was 39.3%. Eleven of 37 PET responders achieved a pathologic complete response (pCR), but only two of 22 PET non-responders did (univariate logistic regression; odds ratio: 4.25, 95% confidence interval: 0.83-21.77; p = 0.08). PET responders to IC had significantly longer overall survival (OS) than PET nonresponders (log-rank p = 0.009). PET response after chemoradiation was not correlated with OS (log-rank p = 0.15). CONCLUSION: Early PET response after IC is prognostic, but subsequent PET changes (for example, after chemoradiation) are not prognostic. Early PET response might have the potential of predicting pCR.
RCT Entities:
BACKGROUND: Early metabolic response after preoperative induction chemotherapy (IC) appears to predict histologic response and prognosis in esophageal cancer (EC), but the usefulness of this approach needs further development. OBJECTIVE: We evaluated metabolic response after one cycle of IC using positron emission tomography (PET) to correlate PET response and outcomes. PATIENTS AND METHODS: We retrospectively analyzed PET data from a randomized phase 2 trial (NCT00525915) of chemoradiation and surgery with or without IC for the treatment of EC. PET was performed at baseline, after one cycle of IC, and 5-7 weeks after chemoradiation. The relationship between PET response (≥35% reduction in standardized uptake value [SUV]) after IC and treatment response was analyzed. RESULTS: In 63 patients who received IC, the mean initial SUVmax prior to treatment was 11.9 ± 8.04 and mean SUVmax after one cycle of IC was 6.47 ± 4.45. The mean SUV reduction after IC was 39.3%. Eleven of 37 PET responders achieved a pathologic complete response (pCR), but only two of 22 PET non-responders did (univariate logistic regression; odds ratio: 4.25, 95% confidence interval: 0.83-21.77; p = 0.08). PET responders to IC had significantly longer overall survival (OS) than PET nonresponders (log-rank p = 0.009). PET response after chemoradiation was not correlated with OS (log-rank p = 0.15). CONCLUSION: Early PET response after IC is prognostic, but subsequent PET changes (for example, after chemoradiation) are not prognostic. Early PET response might have the potential of predicting pCR.
Authors: J A Ajani; L Xiao; J A Roth; W L Hofstetter; G Walsh; R Komaki; Z Liao; D C Rice; A A Vaporciyan; D M Maru; J H Lee; M S Bhutani; A Eid; J C Yao; A P Phan; A Halpin; A Suzuki; T Taketa; P F Thall; S G Swisher Journal: Ann Oncol Date: 2013-08-23 Impact factor: 32.976
Authors: David H Ilson; Bruce D Minsky; Geoffrey Y Ku; Valerie Rusch; Nabil Rizk; Manish Shah; David P Kelsen; Marinela Capanu; Laura Tang; Jenny Campbell; Manjit Bains Journal: Cancer Date: 2011-10-11 Impact factor: 6.860
Authors: Helen M Heneghan; Claire Donohoe; Jessie Elliot; Zuhair Ahmed; Vinod Malik; Narayamasamy Ravi; John V Reynolds Journal: Ann Surg Date: 2016-11 Impact factor: 12.969
Authors: W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: J A Elliott; N J O'Farrell; S King; D Halpenny; V Malik; C Muldoon; C Johnston; J V Reynolds Journal: Br J Surg Date: 2014-10-28 Impact factor: 6.939
Authors: Stephen G Swisher; Jennifer Moughan; Ritsuko U Komaki; Jaffer A Ajani; Tsung T Wu; Wayne L Hofstetter; Andre A Konski; Christopher G Willett Journal: J Thorac Oncol Date: 2016-10-08 Impact factor: 15.609
Authors: John M Findlay; Richard S Gillies; James M Franklin; Eugene J Teoh; Greg E Jones; Sara di Carlo; Fergus V Gleeson; Nicholas D Maynard; Kevin M Bradley; Mark R Middleton Journal: Eur Radiol Date: 2016-02-16 Impact factor: 5.315
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Kazuto Harada; Madhavi Patnana; Xuemei Wang; Masaaki Iwatsuki; Mariela A Blum Murphy; Meina Zhao; Prajnan Das; Bruce D Minsky; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Jeannelyn S Estrella; Namita Shanbhag; Naruhiko Ikoma; Brian D Badgwell; Jaffer A Ajani Journal: Surg Today Date: 2020-05-14 Impact factor: 2.540